2025-08-08T23:03:47.045919+0800 INFO SYS-Warmup function started
2025-08-08T23:03:47.046591+0800 INFO CONFIG-Config path: configs/test_standard.json
2025-08-08T23:03:47.046693+0800 INFO CONFIG-Config: {'chat_config': {'chat_model': 'Qwen/Qwen3-8B', 'lora': False, 'chat_model_type': 'instruction', 'chat_model_inference_engine': 'openai_compatible', 'chat_system_message': 'You are a helpful assistant.', 'chat_parameters': {'temperature': 0.6}, 'chat_max_new_token': 500, 'chat_request_timeout': 60}, 'emb_config': {'emb_model_name': 'Qwen/Qwen3-Embedding-4B', 'emb_size': 2560, 'embedding_timeout': 60}, 'env_config': {'trading_symbols': ['JNJ'], 'warmup_start_time': '2020-03-12', 'warmup_end_time': '2020-03-20', 'test_start_time': '2020-03-23', 'test_end_time': '2020-03-31', 'momentum_window_size': 3, 'env_data_path': {'JNJ': 'data/jnj.json'}}, 'portfolio_config': {'trading_symbols': ['JNJ'], 'type': 'single-asset', 'cash': 100000, 'look_back_window_size': 3}, 'agent_config': {'agent_name': 'test_agent', 'trading_symbols': ['JNJ'], 'character_string': {'JNJ': 'You are an investment expert of Johnson & Johnson (JNJ). You have knowledge about pharmaceuticals, medical devices, and consumer health sectors.'}, 'top_k': 5, 'memory_db_config': {'memory_db_endpoint': 'http://localhost:6333', 'memory_importance_upper_bound': 100.0, 'memory_importance_score_update_step': 18.0, 'trading_symbols': ['JNJ'], 'short': {'db_name': 'short', 'importance_init_val': 50.0, 'decay_recency_factor': 3.0, 'decay_importance_factor': 0.92, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_upper_threshold': 55.0}, 'mid': {'db_name': 'mid', 'importance_init_val': 60.0, 'decay_recency_factor': 90.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 55.0, 'jump_upper_threshold': 85.0}, 'long': {'db_name': 'long', 'importance_init_val': 90.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.96, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'jump_lower_threshold': 85.0}, 'reflection': {'db_name': 'reflection', 'importance_init_val': 80.0, 'decay_recency_factor': 365.0, 'decay_importance_factor': 0.98, 'clean_up_recency_threshold': 0.05, 'clean_up_importance_threshold': 5.0, 'similarity_threshold': 0.95}}}, 'meta_config': {'run_name': '250808_230347_Qwen_Qwen3-8B_JNJ', 'timestamp': '250808_230347', 'model_name': 'Qwen_Qwen3-8B', 'symbols': 'JNJ', 'base_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ', 'momentum_window_size': 3, 'warmup_checkpoint_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint', 'warmup_output_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output', 'test_checkpoint_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/test_checkpoint', 'test_output_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/test_output', 'result_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/final_result', 'log_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/log', 'report_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/report.md', 'csv_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/trading_results.csv', 'charts_save_path': 'results/250808_230347_Qwen_Qwen3-8B_JNJ/charts'}}
2025-08-08T23:03:47.046830+0800 INFO ENV-Creating MarketEnvironment with params: env_data_pkl {'JNJ': 'data/jnj.json'}, start_date 2020-03-12, end_date 2020-03-20, symbol ['JNJ']
2025-08-08T23:03:47.048372+0800 INFO ENV-Final date series (intersection): [datetime.date(2020, 3, 12), datetime.date(2020, 3, 13), datetime.date(2020, 3, 16), datetime.date(2020, 3, 17), datetime.date(2020, 3, 18), datetime.date(2020, 3, 19), datetime.date(2020, 3, 20)]
2025-08-08T23:03:47.048415+0800 INFO ENV-Simulation-Length: 7
2025-08-08T23:03:47.048452+0800 INFO SYS-Initializing FinMemAgent
2025-08-08T23:03:47.048531+0800 INFO SYS-Initializing MemoryDB
2025-08-08T23:03:47.203001+0800 INFO SYS-Portfolio type: single-asset
2025-08-08T23:03:47.204904+0800 INFO **************************************************
2025-08-08T23:03:47.204972+0800 INFO ENV- current date: 2020-03-12, future date: 2020-03-13
2025-08-08T23:03:47.205075+0800 INFO ENV-Current price: {'JNJ': 111.58531188964844}, future price diff: {'JNJ': -0.07080763942400062}
2025-08-08T23:03:47.205151+0800 INFO ENV-Current news: {'JNJ': None}
2025-08-08T23:03:47.205226+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:03:47.205292+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:03:47.205378+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:03:47.205479+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:03:47.205612+0800 INFO ENV-new info from env
2025-08-08T23:03:47.205638+0800 INFO ENV-date: 2020-03-12
2025-08-08T23:03:47.205660+0800 INFO ENV-price: {'JNJ': 111.58531188964844}
2025-08-08T23:03:47.205682+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:03:47.205702+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:03:47.205721+0800 INFO ==================================================
2025-08-08T23:03:47.205748+0800 INFO AGENT-Step, date: 2020-03-12, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:03:47.205770+0800 INFO AGENT-Handling new information
2025-08-08T23:03:47.205801+0800 INFO AGENT-Querying memories
2025-08-08T23:03:48.675697+0800 INFO ##################################################
2025-08-08T23:03:48.675863+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:03:48.675928+0800 INFO AGENT-Single asset task
2025-08-08T23:04:21.547649+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:04:22.018250+0800 INFO AGENT-action: TradeAction.SELL
2025-08-08T23:04:22.018361+0800 INFO AGENT-summary reason: The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:04:22.018731+0800 INFO AGENT-feedback: {'access_counter_records': []}
2025-08-08T23:04:22.090079+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/agent/memory_db/brain
2025-08-08T23:04:22.096397+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:04:22.096533+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:04:22.096637+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:04:22.096884+0800 INFO **************************************************
2025-08-08T23:04:22.097010+0800 INFO ENV- current date: 2020-03-13, future date: 2020-03-16
2025-08-08T23:04:22.097188+0800 INFO ENV-Current price: {'JNJ': 119.48640441894531}, future price diff: {'JNJ': 0.053317529644049205}
2025-08-08T23:04:22.097240+0800 INFO ENV-Current news: {'JNJ': ["Charlotte's Web Holdings, Inc. has launched CW Labs, a new R&D division focused on advancing the science of hemp-derived phytocannabinoids, under the leadership of Tim Orr, a former executive at Johnson & Johnson (JNJ) and Abbott Laboratories. Orr's extensive experience in diagnostics, life sciences, and medical devices positions him to drive innovation and product development at CW Labs. The division will conduct double-blinded, placebo-controlled human clinical trials to explore the safety and efficacy of hemp-based solutions. This initiative underscores Charlotte's Web's commitment to scientific research and product innovation, potentially enhancing its market position. Investors in JNJ might note Orr's transition to a leading role in a growing sector, reflecting the broader trend of experienced executives moving into the burgeoning hemp and CBD industry. (Sentiment: positive)", "Johnson & Johnson's Janssen Pharmaceutical Companies have partnered with Beth Israel Deaconess Medical Center to accelerate the development of a COVID-19 vaccine, with preclinical testing already underway and a potential candidate for clinical trials expected by the end of the month. Janssen aims to initiate a Phase 1 clinical study by the end of the year and is preparing to upscale production to meet global vaccination needs. The collaboration leverages Janssen's proven vaccine technologies, previously used for Ebola, Zika, RSV, and HIV vaccines. This effort is supported by existing collaborations with BARDA and other global partners to expedite vaccine and treatment development. Investors should note the inherent risks in product development, regulatory approvals, and market competition, as highlighted in the company's forward-looking statements. (Sentiment: positive)", 'The "Low Back Pain Clinical Trials Review: H1, 2020" report provides a comprehensive overview of global clinical trials for low back pain, including data on trial numbers, average enrollment, and trial phases across various regions and countries. Johnson & Johnson (JNJ) is listed among the top companies participating in these clinical trials, indicating their active involvement in developing therapeutics for low back pain. The report highlights trends in trial statuses, phases, and sponsor types, offering insights into the competitive landscape and potential areas of growth. Additionally, it includes information on unaccomplished trials, providing reasons for termination, suspension, or withdrawal, which could impact JNJ\'s strategic decisions. This data is crucial for investors to assess JNJ\'s position and potential in the low back pain therapeutics market. (Sentiment: neutral)', 'The "Venous Thromboembolism Global Clinical Trials Review, H1, 2020" report provides a comprehensive overview of the clinical trials landscape for venous thromboembolism, including data on trial numbers, average enrollment, and regional distribution. It highlights the involvement of top pharmaceutical companies, including Johnson & Johnson (JNJ), in ongoing trials. The report details the status and phases of these trials, as well as the reasons for any unaccomplished trials. Additionally, it offers insights into enrollment trends over the past five years and the latest news from the past three months. This information is crucial for investors evaluating JNJ\'s position and potential in the venous thromboembolism therapeutics market. (Sentiment: neutral)']}
2025-08-08T23:04:22.097324+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:04:22.097350+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:04:22.097374+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:04:22.097396+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:04:22.097443+0800 INFO ENV-new info from env
2025-08-08T23:04:22.097468+0800 INFO ENV-date: 2020-03-13
2025-08-08T23:04:22.097491+0800 INFO ENV-price: {'JNJ': 119.48640441894531}
2025-08-08T23:04:22.097515+0800 INFO ENV-news-JNJ-0: Charlotte's Web Holdings, Inc. has launched CW Labs, a new R&D division focused on advancing the science of hemp-derived phytocannabinoids, under the leadership of Tim Orr, a former executive at Johnson & Johnson (JNJ) and Abbott Laboratories. Orr's extensive experience in diagnostics, life sciences, and medical devices positions him to drive innovation and product development at CW Labs. The division will conduct double-blinded, placebo-controlled human clinical trials to explore the safety and efficacy of hemp-based solutions. This initiative underscores Charlotte's Web's commitment to scientific research and product innovation, potentially enhancing its market position. Investors in JNJ might note Orr's transition to a leading role in a growing sector, reflecting the broader trend of experienced executives moving into the burgeoning hemp and CBD industry. (Sentiment: positive)
2025-08-08T23:04:22.097539+0800 INFO --------------------------------------------------
2025-08-08T23:04:22.097561+0800 INFO ENV-news-JNJ-1: Johnson & Johnson's Janssen Pharmaceutical Companies have partnered with Beth Israel Deaconess Medical Center to accelerate the development of a COVID-19 vaccine, with preclinical testing already underway and a potential candidate for clinical trials expected by the end of the month. Janssen aims to initiate a Phase 1 clinical study by the end of the year and is preparing to upscale production to meet global vaccination needs. The collaboration leverages Janssen's proven vaccine technologies, previously used for Ebola, Zika, RSV, and HIV vaccines. This effort is supported by existing collaborations with BARDA and other global partners to expedite vaccine and treatment development. Investors should note the inherent risks in product development, regulatory approvals, and market competition, as highlighted in the company's forward-looking statements. (Sentiment: positive)
2025-08-08T23:04:22.097588+0800 INFO --------------------------------------------------
2025-08-08T23:04:22.097610+0800 INFO ENV-news-JNJ-2: The "Low Back Pain Clinical Trials Review: H1, 2020" report provides a comprehensive overview of global clinical trials for low back pain, including data on trial numbers, average enrollment, and trial phases across various regions and countries. Johnson & Johnson (JNJ) is listed among the top companies participating in these clinical trials, indicating their active involvement in developing therapeutics for low back pain. The report highlights trends in trial statuses, phases, and sponsor types, offering insights into the competitive landscape and potential areas of growth. Additionally, it includes information on unaccomplished trials, providing reasons for termination, suspension, or withdrawal, which could impact JNJ's strategic decisions. This data is crucial for investors to assess JNJ's position and potential in the low back pain therapeutics market. (Sentiment: neutral)
2025-08-08T23:04:22.097636+0800 INFO --------------------------------------------------
2025-08-08T23:04:22.097656+0800 INFO ENV-news-JNJ-3: The "Venous Thromboembolism Global Clinical Trials Review, H1, 2020" report provides a comprehensive overview of the clinical trials landscape for venous thromboembolism, including data on trial numbers, average enrollment, and regional distribution. It highlights the involvement of top pharmaceutical companies, including Johnson & Johnson (JNJ), in ongoing trials. The report details the status and phases of these trials, as well as the reasons for any unaccomplished trials. Additionally, it offers insights into enrollment trends over the past five years and the latest news from the past three months. This information is crucial for investors evaluating JNJ's position and potential in the venous thromboembolism therapeutics market. (Sentiment: neutral)
2025-08-08T23:04:22.097678+0800 INFO --------------------------------------------------
2025-08-08T23:04:22.097699+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:04:22.097719+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:04:22.097740+0800 INFO ==================================================
2025-08-08T23:04:22.097780+0800 INFO AGENT-Step, date: 2020-03-13, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:04:22.097802+0800 INFO AGENT-Handling new information
2025-08-08T23:04:22.447676+0800 INFO AGENT-Querying memories
2025-08-08T23:04:22.956804+0800 INFO ##################################################
2025-08-08T23:04:22.956917+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:04:22.956975+0800 INFO AGENT-Short Memory: 4, The "Low Back Pain Clinical Trials Review: H1, 2020" report provides a comprehensive overview of global clinical trials for low back pain, including data on trial numbers, average enrollment, and trial phases across various regions and countries. Johnson & Johnson (JNJ) is listed among the top companies participating in these clinical trials, indicating their active involvement in developing therapeutics for low back pain. The report highlights trends in trial statuses, phases, and sponsor types, offering insights into the competitive landscape and potential areas of growth. Additionally, it includes information on unaccomplished trials, providing reasons for termination, suspension, or withdrawal, which could impact JNJ's strategic decisions. This data is crucial for investors to assess JNJ's position and potential in the low back pain therapeutics market. (Sentiment: neutral)
2025-08-08T23:04:22.957074+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:22.957235+0800 INFO AGENT-Short Memory: 5, The "Venous Thromboembolism Global Clinical Trials Review, H1, 2020" report provides a comprehensive overview of the clinical trials landscape for venous thromboembolism, including data on trial numbers, average enrollment, and regional distribution. It highlights the involvement of top pharmaceutical companies, including Johnson & Johnson (JNJ), in ongoing trials. The report details the status and phases of these trials, as well as the reasons for any unaccomplished trials. Additionally, it offers insights into enrollment trends over the past five years and the latest news from the past three months. This information is crucial for investors evaluating JNJ's position and potential in the venous thromboembolism therapeutics market. (Sentiment: neutral)
2025-08-08T23:04:22.957388+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:22.957462+0800 INFO AGENT-Short Memory: 3, Johnson & Johnson's Janssen Pharmaceutical Companies have partnered with Beth Israel Deaconess Medical Center to accelerate the development of a COVID-19 vaccine, with preclinical testing already underway and a potential candidate for clinical trials expected by the end of the month. Janssen aims to initiate a Phase 1 clinical study by the end of the year and is preparing to upscale production to meet global vaccination needs. The collaboration leverages Janssen's proven vaccine technologies, previously used for Ebola, Zika, RSV, and HIV vaccines. This effort is supported by existing collaborations with BARDA and other global partners to expedite vaccine and treatment development. Investors should note the inherent risks in product development, regulatory approvals, and market competition, as highlighted in the company's forward-looking statements. (Sentiment: positive)
2025-08-08T23:04:22.957515+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:22.957561+0800 INFO AGENT-Short Memory: 2, Charlotte's Web Holdings, Inc. has launched CW Labs, a new R&D division focused on advancing the science of hemp-derived phytocannabinoids, under the leadership of Tim Orr, a former executive at Johnson & Johnson (JNJ) and Abbott Laboratories. Orr's extensive experience in diagnostics, life sciences, and medical devices positions him to drive innovation and product development at CW Labs. The division will conduct double-blinded, placebo-controlled human clinical trials to explore the safety and efficacy of hemp-based solutions. This initiative underscores Charlotte's Web's commitment to scientific research and product innovation, potentially enhancing its market position. Investors in JNJ might note Orr's transition to a leading role in a growing sector, reflecting the broader trend of experienced executives moving into the burgeoning hemp and CBD industry. (Sentiment: positive)
2025-08-08T23:04:22.957607+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:22.957649+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:04:22.957691+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:22.957733+0800 INFO AGENT-Single asset task
2025-08-08T23:04:48.269659+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:04:48.664759+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:04:48.664897+0800 INFO AGENT-summary reason: The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:04:48.665445+0800 INFO AGENT-feedback: {'access_counter_records': []}
2025-08-08T23:04:48.763644+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:04:48.764391+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:04:48.764565+0800 INFO **************************************************
2025-08-08T23:04:48.764735+0800 INFO ENV- current date: 2020-03-16, future date: 2020-03-17
2025-08-08T23:04:48.765047+0800 INFO ENV-Current price: {'JNJ': 113.11568450927734}, future price diff: {'JNJ': -0.07441216449229845}
2025-08-08T23:04:48.765191+0800 INFO ENV-Current news: {'JNJ': ["Convert Group, a Greek technology firm, has developed a solution to address the availability and price fluctuations of COVID-19 sensitive products in online pharmacies and groceries, which has been successfully implemented in Italy, Spain, and Greece. The company is now offering this solution globally under an Enterprise Software-as-a-Service model, enabling manufacturers to gain visibility on their digital shelf presence. This technology is particularly relevant for major Consumer Healthcare and FMCG firms, including Johnson & Johnson (JNJ), which is one of the partners. The platform's rapid setup, driven by AI and machine learning, allows for quick adaptation to market demands, which have surged significantly for COVID-19 related products. This development could enhance JNJ's ability to manage product availability and pricing, potentially leading to improved market performance during the pandemic. (Sentiment: positive)", "The new research report by Safe Kids Worldwide, supported by Johnson & Johnson Consumer Inc., reveals that over 47,000 children under age 6 are seen in emergency rooms annually for medicine poisoning, equating to five children every hour. The report highlights common misconceptions about medicine safety and provides actionable steps for parents to prevent such incidents, emphasizing the importance of storing medicine out of children's reach and using child-resistant packaging. This underscores the critical role of Johnson & Johnson's consumer health products in addressing child safety, potentially enhancing the company's brand reputation and consumer trust. The findings may drive increased demand for child-resistant packaging and safety-focused products, presenting a growth opportunity for Johnson & Johnson. Investors should consider the positive impact of these safety initiatives on J&J's market position and long-term profitability. (Sentiment: positive)", "Centinel Spine, LLC has appointed Steven F. Murray as CEO, effective March 16, 2020, succeeding John J. Viscogliosi. Murray, an industry veteran with over 25 years of experience in orthopedics and 20 years as an executive, was most recently President of Advanced Sterilization Products at Johnson & Johnson. Under Viscogliosi's leadership, Centinel Spine achieved record revenue in 2019 and established significant partnerships, including with Tiger Woods, to enhance public education on spinal disease. The company, known for its pioneering technology in anterior column reconstruction, recently acquired the prodisc Total Disc Replacement Technology Platform, solidifying its position as a leader in both cervical and lumbar motion-preserving and fusion solutions. This leadership change and strategic acquisitions indicate potential growth and innovation, making Centinel Spine a company to watch in the spine industry. (Sentiment: positive)", 'The global smoking cessation and nicotine de-addiction market is projected to grow by USD 16.6 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 13%. Key growth drivers include an increasing number of people attempting to quit smoking and product innovations. The market is segmented by product types such as e-cigarettes, NRT, and drug therapy, and geographically across APAC, Europe, MEA, North America, and South America. Prominent vendors include Johnson & Johnson Services Inc. (JNJ), along with other major players like British American Tobacco Plc and GlaxoSmithKline Plc. The report provides a comprehensive analysis of market trends, growth drivers, challenges, and a detailed vendor landscape. (Sentiment: positive)']}
2025-08-08T23:04:48.765415+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:04:48.765525+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:04:48.765586+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:04:48.765640+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:04:48.765746+0800 INFO ENV-new info from env
2025-08-08T23:04:48.765810+0800 INFO ENV-date: 2020-03-16
2025-08-08T23:04:48.765866+0800 INFO ENV-price: {'JNJ': 113.11568450927734}
2025-08-08T23:04:48.765927+0800 INFO ENV-news-JNJ-0: Convert Group, a Greek technology firm, has developed a solution to address the availability and price fluctuations of COVID-19 sensitive products in online pharmacies and groceries, which has been successfully implemented in Italy, Spain, and Greece. The company is now offering this solution globally under an Enterprise Software-as-a-Service model, enabling manufacturers to gain visibility on their digital shelf presence. This technology is particularly relevant for major Consumer Healthcare and FMCG firms, including Johnson & Johnson (JNJ), which is one of the partners. The platform's rapid setup, driven by AI and machine learning, allows for quick adaptation to market demands, which have surged significantly for COVID-19 related products. This development could enhance JNJ's ability to manage product availability and pricing, potentially leading to improved market performance during the pandemic. (Sentiment: positive)
2025-08-08T23:04:48.765986+0800 INFO --------------------------------------------------
2025-08-08T23:04:48.766057+0800 INFO ENV-news-JNJ-1: The new research report by Safe Kids Worldwide, supported by Johnson & Johnson Consumer Inc., reveals that over 47,000 children under age 6 are seen in emergency rooms annually for medicine poisoning, equating to five children every hour. The report highlights common misconceptions about medicine safety and provides actionable steps for parents to prevent such incidents, emphasizing the importance of storing medicine out of children's reach and using child-resistant packaging. This underscores the critical role of Johnson & Johnson's consumer health products in addressing child safety, potentially enhancing the company's brand reputation and consumer trust. The findings may drive increased demand for child-resistant packaging and safety-focused products, presenting a growth opportunity for Johnson & Johnson. Investors should consider the positive impact of these safety initiatives on J&J's market position and long-term profitability. (Sentiment: positive)
2025-08-08T23:04:48.766146+0800 INFO --------------------------------------------------
2025-08-08T23:04:48.766212+0800 INFO ENV-news-JNJ-2: Centinel Spine, LLC has appointed Steven F. Murray as CEO, effective March 16, 2020, succeeding John J. Viscogliosi. Murray, an industry veteran with over 25 years of experience in orthopedics and 20 years as an executive, was most recently President of Advanced Sterilization Products at Johnson & Johnson. Under Viscogliosi's leadership, Centinel Spine achieved record revenue in 2019 and established significant partnerships, including with Tiger Woods, to enhance public education on spinal disease. The company, known for its pioneering technology in anterior column reconstruction, recently acquired the prodisc Total Disc Replacement Technology Platform, solidifying its position as a leader in both cervical and lumbar motion-preserving and fusion solutions. This leadership change and strategic acquisitions indicate potential growth and innovation, making Centinel Spine a company to watch in the spine industry. (Sentiment: positive)
2025-08-08T23:04:48.766290+0800 INFO --------------------------------------------------
2025-08-08T23:04:48.766355+0800 INFO ENV-news-JNJ-3: The global smoking cessation and nicotine de-addiction market is projected to grow by USD 16.6 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 13%. Key growth drivers include an increasing number of people attempting to quit smoking and product innovations. The market is segmented by product types such as e-cigarettes, NRT, and drug therapy, and geographically across APAC, Europe, MEA, North America, and South America. Prominent vendors include Johnson & Johnson Services Inc. (JNJ), along with other major players like British American Tobacco Plc and GlaxoSmithKline Plc. The report provides a comprehensive analysis of market trends, growth drivers, challenges, and a detailed vendor landscape. (Sentiment: positive)
2025-08-08T23:04:48.766424+0800 INFO --------------------------------------------------
2025-08-08T23:04:48.766489+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:04:48.766554+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:04:48.766620+0800 INFO ==================================================
2025-08-08T23:04:48.766721+0800 INFO AGENT-Step, date: 2020-03-16, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:04:48.766790+0800 INFO AGENT-Handling new information
2025-08-08T23:04:49.094104+0800 INFO AGENT-Querying memories
2025-08-08T23:04:49.619521+0800 INFO ##################################################
2025-08-08T23:04:49.619626+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:04:49.619665+0800 INFO AGENT-Short Memory: 7, Convert Group, a Greek technology firm, has developed a solution to address the availability and price fluctuations of COVID-19 sensitive products in online pharmacies and groceries, which has been successfully implemented in Italy, Spain, and Greece. The company is now offering this solution globally under an Enterprise Software-as-a-Service model, enabling manufacturers to gain visibility on their digital shelf presence. This technology is particularly relevant for major Consumer Healthcare and FMCG firms, including Johnson & Johnson (JNJ), which is one of the partners. The platform's rapid setup, driven by AI and machine learning, allows for quick adaptation to market demands, which have surged significantly for COVID-19 related products. This development could enhance JNJ's ability to manage product availability and pricing, potentially leading to improved market performance during the pandemic. (Sentiment: positive)
2025-08-08T23:04:49.619725+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.619755+0800 INFO AGENT-Short Memory: 8, The new research report by Safe Kids Worldwide, supported by Johnson & Johnson Consumer Inc., reveals that over 47,000 children under age 6 are seen in emergency rooms annually for medicine poisoning, equating to five children every hour. The report highlights common misconceptions about medicine safety and provides actionable steps for parents to prevent such incidents, emphasizing the importance of storing medicine out of children's reach and using child-resistant packaging. This underscores the critical role of Johnson & Johnson's consumer health products in addressing child safety, potentially enhancing the company's brand reputation and consumer trust. The findings may drive increased demand for child-resistant packaging and safety-focused products, presenting a growth opportunity for Johnson & Johnson. Investors should consider the positive impact of these safety initiatives on J&J's market position and long-term profitability. (Sentiment: positive)
2025-08-08T23:04:49.619793+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.619822+0800 INFO AGENT-Short Memory: 9, Centinel Spine, LLC has appointed Steven F. Murray as CEO, effective March 16, 2020, succeeding John J. Viscogliosi. Murray, an industry veteran with over 25 years of experience in orthopedics and 20 years as an executive, was most recently President of Advanced Sterilization Products at Johnson & Johnson. Under Viscogliosi's leadership, Centinel Spine achieved record revenue in 2019 and established significant partnerships, including with Tiger Woods, to enhance public education on spinal disease. The company, known for its pioneering technology in anterior column reconstruction, recently acquired the prodisc Total Disc Replacement Technology Platform, solidifying its position as a leader in both cervical and lumbar motion-preserving and fusion solutions. This leadership change and strategic acquisitions indicate potential growth and innovation, making Centinel Spine a company to watch in the spine industry. (Sentiment: positive)
2025-08-08T23:04:49.619867+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.619946+0800 INFO AGENT-Short Memory: 10, The global smoking cessation and nicotine de-addiction market is projected to grow by USD 16.6 billion from 2020 to 2024, with a compound annual growth rate (CAGR) of 13%. Key growth drivers include an increasing number of people attempting to quit smoking and product innovations. The market is segmented by product types such as e-cigarettes, NRT, and drug therapy, and geographically across APAC, Europe, MEA, North America, and South America. Prominent vendors include Johnson & Johnson Services Inc. (JNJ), along with other major players like British American Tobacco Plc and GlaxoSmithKline Plc. The report provides a comprehensive analysis of market trends, growth drivers, challenges, and a detailed vendor landscape. (Sentiment: positive)
2025-08-08T23:04:49.620082+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.620138+0800 INFO AGENT-Short Memory: 4, The "Low Back Pain Clinical Trials Review: H1, 2020" report provides a comprehensive overview of global clinical trials for low back pain, including data on trial numbers, average enrollment, and trial phases across various regions and countries. Johnson & Johnson (JNJ) is listed among the top companies participating in these clinical trials, indicating their active involvement in developing therapeutics for low back pain. The report highlights trends in trial statuses, phases, and sponsor types, offering insights into the competitive landscape and potential areas of growth. Additionally, it includes information on unaccomplished trials, providing reasons for termination, suspension, or withdrawal, which could impact JNJ's strategic decisions. This data is crucial for investors to assess JNJ's position and potential in the low back pain therapeutics market. (Sentiment: neutral)
2025-08-08T23:04:49.620178+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.620206+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:04:49.620237+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.620262+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:04:49.620285+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:04:49.620313+0800 INFO AGENT-Single asset task
2025-08-08T23:05:19.845043+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:05:20.310593+0800 INFO AGENT-action: TradeAction.SELL
2025-08-08T23:05:20.310719+0800 INFO AGENT-summary reason: The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:05:20.311148+0800 INFO AGENT-feedback: {'access_counter_records': []}
2025-08-08T23:05:20.396136+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:05:20.396387+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:05:20.396482+0800 INFO **************************************************
2025-08-08T23:05:20.396555+0800 INFO ENV- current date: 2020-03-17, future date: 2020-03-18
2025-08-08T23:05:20.396792+0800 INFO ENV-Current price: {'JNJ': 121.53286743164062}, future price diff: {'JNJ': 0.011933477618585226}
2025-08-08T23:05:20.396851+0800 INFO ENV-Current news: {'JNJ': ['The global market for surgical robotic systems, including capital equipment, service, and training, was valued at $2.63 billion in 2019 and is projected to grow at an annual rate of 18.2% to reach $6.07 billion by 2024. Laparoscopic systems will remain the dominant segment due to their wide application, but bronchoscopic and cardiovascular robotic systems are expected to see the fastest growth. Johnson & Johnson, through its subsidiary Verb Surgical, is a key player in the laparoscopic robotic systems market, which is poised for significant expansion. The increasing global adoption of robotic surgery technologies is driven by the need for more predictable surgical outcomes, particularly in complex cases. This growth trend presents a substantial investment opportunity in the surgical robotics sector, particularly for companies like Johnson & Johnson that are well-positioned in this market. (Sentiment: positive)', "Johnson & Johnson (NYSE: JNJ) will host an investor conference call on April 14, 2020, at 8:30 a.m. ET to review their first-quarter results, with key executives including CFO Joseph J. Wolk and VP of Investor Relations Christopher DelOrefice leading the call. The call will include a Q&A session with additional members of the executive team. Investors can access the webcast and presentation materials on the company's investor website, with a replay available shortly after the call. The press release detailing the results will be available at 6:45 a.m. ET on the same day. This call is crucial for investors to gain insights into the company's financial performance and strategic direction, which can inform investment decisions. (Sentiment: neutral)"]}
2025-08-08T23:05:20.396918+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:05:20.396972+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:05:20.397019+0800 INFO ENV-Current momentum: {'JNJ': None}
2025-08-08T23:05:20.397068+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:05:20.397152+0800 INFO ENV-new info from env
2025-08-08T23:05:20.397204+0800 INFO ENV-date: 2020-03-17
2025-08-08T23:05:20.397252+0800 INFO ENV-price: {'JNJ': 121.53286743164062}
2025-08-08T23:05:20.397312+0800 INFO ENV-news-JNJ-0: The global market for surgical robotic systems, including capital equipment, service, and training, was valued at $2.63 billion in 2019 and is projected to grow at an annual rate of 18.2% to reach $6.07 billion by 2024. Laparoscopic systems will remain the dominant segment due to their wide application, but bronchoscopic and cardiovascular robotic systems are expected to see the fastest growth. Johnson & Johnson, through its subsidiary Verb Surgical, is a key player in the laparoscopic robotic systems market, which is poised for significant expansion. The increasing global adoption of robotic surgery technologies is driven by the need for more predictable surgical outcomes, particularly in complex cases. This growth trend presents a substantial investment opportunity in the surgical robotics sector, particularly for companies like Johnson & Johnson that are well-positioned in this market. (Sentiment: positive)
2025-08-08T23:05:20.397377+0800 INFO --------------------------------------------------
2025-08-08T23:05:20.397424+0800 INFO ENV-news-JNJ-1: Johnson & Johnson (NYSE: JNJ) will host an investor conference call on April 14, 2020, at 8:30 a.m. ET to review their first-quarter results, with key executives including CFO Joseph J. Wolk and VP of Investor Relations Christopher DelOrefice leading the call. The call will include a Q&A session with additional members of the executive team. Investors can access the webcast and presentation materials on the company's investor website, with a replay available shortly after the call. The press release detailing the results will be available at 6:45 a.m. ET on the same day. This call is crucial for investors to gain insights into the company's financial performance and strategic direction, which can inform investment decisions. (Sentiment: neutral)
2025-08-08T23:05:20.397470+0800 INFO --------------------------------------------------
2025-08-08T23:05:20.397514+0800 INFO ENV-momentum: {'JNJ': None}
2025-08-08T23:05:20.397558+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:05:20.397600+0800 INFO ==================================================
2025-08-08T23:05:20.397662+0800 INFO AGENT-Step, date: 2020-03-17, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:05:20.397702+0800 INFO AGENT-Handling new information
2025-08-08T23:05:20.648662+0800 INFO AGENT-Querying memories
2025-08-08T23:05:21.243595+0800 INFO ##################################################
2025-08-08T23:05:21.243758+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:05:21.243825+0800 INFO AGENT-Short Memory: 13, Johnson & Johnson (NYSE: JNJ) will host an investor conference call on April 14, 2020, at 8:30 a.m. ET to review their first-quarter results, with key executives including CFO Joseph J. Wolk and VP of Investor Relations Christopher DelOrefice leading the call. The call will include a Q&A session with additional members of the executive team. Investors can access the webcast and presentation materials on the company's investor website, with a replay available shortly after the call. The press release detailing the results will be available at 6:45 a.m. ET on the same day. This call is crucial for investors to gain insights into the company's financial performance and strategic direction, which can inform investment decisions. (Sentiment: neutral)
2025-08-08T23:05:21.243887+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.243940+0800 INFO AGENT-Short Memory: 12, The global market for surgical robotic systems, including capital equipment, service, and training, was valued at $2.63 billion in 2019 and is projected to grow at an annual rate of 18.2% to reach $6.07 billion by 2024. Laparoscopic systems will remain the dominant segment due to their wide application, but bronchoscopic and cardiovascular robotic systems are expected to see the fastest growth. Johnson & Johnson, through its subsidiary Verb Surgical, is a key player in the laparoscopic robotic systems market, which is poised for significant expansion. The increasing global adoption of robotic surgery technologies is driven by the need for more predictable surgical outcomes, particularly in complex cases. This growth trend presents a substantial investment opportunity in the surgical robotics sector, particularly for companies like Johnson & Johnson that are well-positioned in this market. (Sentiment: positive)
2025-08-08T23:05:21.243995+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244054+0800 INFO AGENT-Short Memory: 7, Convert Group, a Greek technology firm, has developed a solution to address the availability and price fluctuations of COVID-19 sensitive products in online pharmacies and groceries, which has been successfully implemented in Italy, Spain, and Greece. The company is now offering this solution globally under an Enterprise Software-as-a-Service model, enabling manufacturers to gain visibility on their digital shelf presence. This technology is particularly relevant for major Consumer Healthcare and FMCG firms, including Johnson & Johnson (JNJ), which is one of the partners. The platform's rapid setup, driven by AI and machine learning, allows for quick adaptation to market demands, which have surged significantly for COVID-19 related products. This development could enhance JNJ's ability to manage product availability and pricing, potentially leading to improved market performance during the pandemic. (Sentiment: positive)
2025-08-08T23:05:21.244104+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244150+0800 INFO AGENT-Short Memory: 8, The new research report by Safe Kids Worldwide, supported by Johnson & Johnson Consumer Inc., reveals that over 47,000 children under age 6 are seen in emergency rooms annually for medicine poisoning, equating to five children every hour. The report highlights common misconceptions about medicine safety and provides actionable steps for parents to prevent such incidents, emphasizing the importance of storing medicine out of children's reach and using child-resistant packaging. This underscores the critical role of Johnson & Johnson's consumer health products in addressing child safety, potentially enhancing the company's brand reputation and consumer trust. The findings may drive increased demand for child-resistant packaging and safety-focused products, presenting a growth opportunity for Johnson & Johnson. Investors should consider the positive impact of these safety initiatives on J&J's market position and long-term profitability. (Sentiment: positive)
2025-08-08T23:05:21.244218+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244269+0800 INFO AGENT-Short Memory: 9, Centinel Spine, LLC has appointed Steven F. Murray as CEO, effective March 16, 2020, succeeding John J. Viscogliosi. Murray, an industry veteran with over 25 years of experience in orthopedics and 20 years as an executive, was most recently President of Advanced Sterilization Products at Johnson & Johnson. Under Viscogliosi's leadership, Centinel Spine achieved record revenue in 2019 and established significant partnerships, including with Tiger Woods, to enhance public education on spinal disease. The company, known for its pioneering technology in anterior column reconstruction, recently acquired the prodisc Total Disc Replacement Technology Platform, solidifying its position as a leader in both cervical and lumbar motion-preserving and fusion solutions. This leadership change and strategic acquisitions indicate potential growth and innovation, making Centinel Spine a company to watch in the spine industry. (Sentiment: positive)
2025-08-08T23:05:21.244319+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244365+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:05:21.244413+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244458+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:05:21.244516+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244561+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:05:21.244607+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:05:21.244654+0800 INFO AGENT-Single asset task
2025-08-08T23:06:18.207151+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:06:18.675649+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:06:18.675788+0800 INFO AGENT-summary reason: The price fluctuation of 0.011933 for JNJ is not directly explained by the provided information. The available data includes neutral clinical trial details, positive news about partnerships and safety initiatives (IDs 7, 8), and a future investor call (ID 13). However, none of these factors are explicitly tied to the immediate price movement. The reflection-term information (IDs 1, 6, 11) indicates that such fluctuations may stem from broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:06:18.676575+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 6, 'feedback': 1}]}
2025-08-08T23:06:18.774677+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:06:18.774888+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:06:18.774977+0800 INFO **************************************************
2025-08-08T23:06:18.775036+0800 INFO ENV- current date: 2020-03-18, future date: 2020-03-19
2025-08-08T23:06:18.775333+0800 INFO ENV-Current price: {'JNJ': 120.08255767822266}, future price diff: {'JNJ': 0.05861007565633918}
2025-08-08T23:06:18.775394+0800 INFO ENV-Current news: {'JNJ': ["The Visiongain report projects the global Rheumatoid Arthritis (RA) drugs market to grow at a CAGR of 0.6% in the latter half of the forecast period, reaching $58 billion in 2018. The biologics submarket, which held 85% of the RA market in 2018, is a significant driver of this growth. Key players in the market include Johnson & Johnson (JNJ), which is well-positioned given its strong portfolio of RA drugs like Remicade and Simponi. The report provides detailed revenue forecasts by drug class, individual drugs, and regions, highlighting North America and Europe as leading markets. Investors should note the market's modest growth rate and the dominance of biologics, which could influence JNJ's strategic focus and investment in this sector. (Sentiment: neutral)", "The global oral care market is projected to grow from USD 34,670 million in 2019 to USD 41,010 million by 2026, at a CAGR of 2.4%, driven by increasing dental health awareness and expenditure, and the rising prevalence of dental diseases. Key market segments include toothbrushes, toothpaste, mouthwash/rinse, denture products, and dental accessories, with toothpaste holding the largest market share. The Asia-Pacific region leads the market due to its large population, followed by Europe and North America. Major players in the market include Johnson & Johnson (JNJ), Procter & Gamble, Colgate-Palmolive, and GlaxoSmithKline. JNJ's involvement in the oral care market, particularly in high-demand regions and innovative product segments, positions it well for potential growth. (Sentiment: positive)", "Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a New Drug Application (NDA) to the U.S. FDA for ponesimod, an investigational treatment for adults with relapsing multiple sclerosis (MS). The NDA is supported by the Phase 3 OPTIMUM study, which demonstrated ponesimod's superior efficacy in reducing annualized relapse rate (ARR) and fatigue symptoms compared to Aubagio. The study also showed a significant reduction in combined unique active lesions (CUALs) in the brain. The safety profile of ponesimod was consistent with previous studies and other S1P receptor modulators. Investors should note the potential market impact given the high prevalence of MS and the unmet needs in its treatment. (Sentiment: positive)"]}
2025-08-08T23:06:18.775470+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:06:18.775505+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:06:18.775538+0800 INFO ENV-Current momentum: {'JNJ': 1}
2025-08-08T23:06:18.775570+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:06:18.775627+0800 INFO ENV-new info from env
2025-08-08T23:06:18.775663+0800 INFO ENV-date: 2020-03-18
2025-08-08T23:06:18.775697+0800 INFO ENV-price: {'JNJ': 120.08255767822266}
2025-08-08T23:06:18.775734+0800 INFO ENV-news-JNJ-0: The Visiongain report projects the global Rheumatoid Arthritis (RA) drugs market to grow at a CAGR of 0.6% in the latter half of the forecast period, reaching $58 billion in 2018. The biologics submarket, which held 85% of the RA market in 2018, is a significant driver of this growth. Key players in the market include Johnson & Johnson (JNJ), which is well-positioned given its strong portfolio of RA drugs like Remicade and Simponi. The report provides detailed revenue forecasts by drug class, individual drugs, and regions, highlighting North America and Europe as leading markets. Investors should note the market's modest growth rate and the dominance of biologics, which could influence JNJ's strategic focus and investment in this sector. (Sentiment: neutral)
2025-08-08T23:06:18.775770+0800 INFO --------------------------------------------------
2025-08-08T23:06:18.775879+0800 INFO ENV-news-JNJ-1: The global oral care market is projected to grow from USD 34,670 million in 2019 to USD 41,010 million by 2026, at a CAGR of 2.4%, driven by increasing dental health awareness and expenditure, and the rising prevalence of dental diseases. Key market segments include toothbrushes, toothpaste, mouthwash/rinse, denture products, and dental accessories, with toothpaste holding the largest market share. The Asia-Pacific region leads the market due to its large population, followed by Europe and North America. Major players in the market include Johnson & Johnson (JNJ), Procter & Gamble, Colgate-Palmolive, and GlaxoSmithKline. JNJ's involvement in the oral care market, particularly in high-demand regions and innovative product segments, positions it well for potential growth. (Sentiment: positive)
2025-08-08T23:06:18.775923+0800 INFO --------------------------------------------------
2025-08-08T23:06:18.775962+0800 INFO ENV-news-JNJ-2: Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a New Drug Application (NDA) to the U.S. FDA for ponesimod, an investigational treatment for adults with relapsing multiple sclerosis (MS). The NDA is supported by the Phase 3 OPTIMUM study, which demonstrated ponesimod's superior efficacy in reducing annualized relapse rate (ARR) and fatigue symptoms compared to Aubagio. The study also showed a significant reduction in combined unique active lesions (CUALs) in the brain. The safety profile of ponesimod was consistent with previous studies and other S1P receptor modulators. Investors should note the potential market impact given the high prevalence of MS and the unmet needs in its treatment. (Sentiment: positive)
2025-08-08T23:06:18.776003+0800 INFO --------------------------------------------------
2025-08-08T23:06:18.776041+0800 INFO ENV-momentum: {'JNJ': 1}
2025-08-08T23:06:18.776086+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:06:18.776126+0800 INFO ==================================================
2025-08-08T23:06:18.776185+0800 INFO AGENT-Step, date: 2020-03-18, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:06:18.776224+0800 INFO AGENT-Handling new information
2025-08-08T23:06:20.016887+0800 INFO AGENT-Querying memories
2025-08-08T23:06:20.575331+0800 INFO ##################################################
2025-08-08T23:06:20.575703+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:06:20.575801+0800 INFO AGENT-Short Memory: 17, Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a New Drug Application (NDA) to the U.S. FDA for ponesimod, an investigational treatment for adults with relapsing multiple sclerosis (MS). The NDA is supported by the Phase 3 OPTIMUM study, which demonstrated ponesimod's superior efficacy in reducing annualized relapse rate (ARR) and fatigue symptoms compared to Aubagio. The study also showed a significant reduction in combined unique active lesions (CUALs) in the brain. The safety profile of ponesimod was consistent with previous studies and other S1P receptor modulators. Investors should note the potential market impact given the high prevalence of MS and the unmet needs in its treatment. (Sentiment: positive)
2025-08-08T23:06:20.575892+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.575965+0800 INFO AGENT-Short Memory: 15, The Visiongain report projects the global Rheumatoid Arthritis (RA) drugs market to grow at a CAGR of 0.6% in the latter half of the forecast period, reaching $58 billion in 2018. The biologics submarket, which held 85% of the RA market in 2018, is a significant driver of this growth. Key players in the market include Johnson & Johnson (JNJ), which is well-positioned given its strong portfolio of RA drugs like Remicade and Simponi. The report provides detailed revenue forecasts by drug class, individual drugs, and regions, highlighting North America and Europe as leading markets. Investors should note the market's modest growth rate and the dominance of biologics, which could influence JNJ's strategic focus and investment in this sector. (Sentiment: neutral)
2025-08-08T23:06:20.576039+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576103+0800 INFO AGENT-Short Memory: 16, The global oral care market is projected to grow from USD 34,670 million in 2019 to USD 41,010 million by 2026, at a CAGR of 2.4%, driven by increasing dental health awareness and expenditure, and the rising prevalence of dental diseases. Key market segments include toothbrushes, toothpaste, mouthwash/rinse, denture products, and dental accessories, with toothpaste holding the largest market share. The Asia-Pacific region leads the market due to its large population, followed by Europe and North America. Major players in the market include Johnson & Johnson (JNJ), Procter & Gamble, Colgate-Palmolive, and GlaxoSmithKline. JNJ's involvement in the oral care market, particularly in high-demand regions and innovative product segments, positions it well for potential growth. (Sentiment: positive)
2025-08-08T23:06:20.576180+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576253+0800 INFO AGENT-Short Memory: 13, Johnson & Johnson (NYSE: JNJ) will host an investor conference call on April 14, 2020, at 8:30 a.m. ET to review their first-quarter results, with key executives including CFO Joseph J. Wolk and VP of Investor Relations Christopher DelOrefice leading the call. The call will include a Q&A session with additional members of the executive team. Investors can access the webcast and presentation materials on the company's investor website, with a replay available shortly after the call. The press release detailing the results will be available at 6:45 a.m. ET on the same day. This call is crucial for investors to gain insights into the company's financial performance and strategic direction, which can inform investment decisions. (Sentiment: neutral)
2025-08-08T23:06:20.576336+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576397+0800 INFO AGENT-Short Memory: 12, The global market for surgical robotic systems, including capital equipment, service, and training, was valued at $2.63 billion in 2019 and is projected to grow at an annual rate of 18.2% to reach $6.07 billion by 2024. Laparoscopic systems will remain the dominant segment due to their wide application, but bronchoscopic and cardiovascular robotic systems are expected to see the fastest growth. Johnson & Johnson, through its subsidiary Verb Surgical, is a key player in the laparoscopic robotic systems market, which is poised for significant expansion. The increasing global adoption of robotic surgery technologies is driven by the need for more predictable surgical outcomes, particularly in complex cases. This growth trend presents a substantial investment opportunity in the surgical robotics sector, particularly for companies like Johnson & Johnson that are well-positioned in this market. (Sentiment: positive)
2025-08-08T23:06:20.576470+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576530+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:06:20.576594+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576650+0800 INFO AGENT-Reflection Memory: 14, The price fluctuation of 0.011933 for JNJ is not directly explained by the provided information. The available data includes neutral clinical trial details, positive news about partnerships and safety initiatives (IDs 7, 8), and a future investor call (ID 13). However, none of these factors are explicitly tied to the immediate price movement. The reflection-term information (IDs 1, 6, 11) indicates that such fluctuations may stem from broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:06:20.576712+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576772+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:06:20.576840+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.576901+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:06:20.576961+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:06:20.577027+0800 INFO AGENT-Single asset task
2025-08-08T23:07:56.836657+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:07:57.612913+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:07:57.612967+0800 INFO AGENT-summary reason: The positive price fluctuation of 0.0586 is likely influenced by the positive sentiment from short-term news (IDs 17, 16, 12) highlighting JNJ's advancements in pharmaceuticals (e.g., ponesimod NDA submission, RA drug portfolio strength, and surgical robotics growth). These developments may have boosted investor confidence in JNJ's innovation and market positioning, despite the reflection-term information (IDs 6, 14, 11, 1) noting that broader market factors or unmentioned events could also play a role.
2025-08-08T23:07:57.613190+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 11, 'feedback': 1}]}
2025-08-08T23:07:57.703347+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:07:57.703673+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:07:57.703816+0800 INFO **************************************************
2025-08-08T23:07:57.703907+0800 INFO ENV- current date: 2020-03-19, future date: 2020-03-20
2025-08-08T23:07:57.704452+0800 INFO ENV-Current price: {'JNJ': 113.04450988769531}, future price diff: {'JNJ': 0.0563557191517564}
2025-08-08T23:07:57.704508+0800 INFO ENV-Current news: {'JNJ': ["ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)", 'The global Lateral Flow Assay market is projected to grow by $3.8 billion, driven by a compounded annual growth rate (CAGR) of 7.4%, with the Kits & Reagents segment expected to grow at over 7.7% and reach $5.7 billion by 2025. The United States will maintain a 6.2% growth momentum, while China is expected to grow at 11%, adding approximately $1 billion in market opportunity. Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, and Johnson & Johnson (JNJ). The market growth is driven by factors such as the expanding aging population, increase in chronic diseases, and rising popularity of point-of-care testing. Innovations and product launches in the Lateral Flow Assay space are expected to further drive market growth, making it a promising area for investment. (Sentiment: positive)']}
2025-08-08T23:07:57.704550+0800 INFO ENV-Current filing_k: {'JNJ': None}
2025-08-08T23:07:57.704575+0800 INFO ENV-Current filing_q: {'JNJ': None}
2025-08-08T23:07:57.704599+0800 INFO ENV-Current momentum: {'JNJ': 1}
2025-08-08T23:07:57.704623+0800 INFO ENV-Current symbol: ['JNJ']
2025-08-08T23:07:57.704669+0800 INFO ENV-new info from env
2025-08-08T23:07:57.704694+0800 INFO ENV-date: 2020-03-19
2025-08-08T23:07:57.704717+0800 INFO ENV-price: {'JNJ': 113.04450988769531}
2025-08-08T23:07:57.704740+0800 INFO ENV-news-JNJ-0: ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)
2025-08-08T23:07:57.704764+0800 INFO --------------------------------------------------
2025-08-08T23:07:57.704784+0800 INFO ENV-news-JNJ-1: The global Lateral Flow Assay market is projected to grow by $3.8 billion, driven by a compounded annual growth rate (CAGR) of 7.4%, with the Kits & Reagents segment expected to grow at over 7.7% and reach $5.7 billion by 2025. The United States will maintain a 6.2% growth momentum, while China is expected to grow at 11%, adding approximately $1 billion in market opportunity. Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, and Johnson & Johnson (JNJ). The market growth is driven by factors such as the expanding aging population, increase in chronic diseases, and rising popularity of point-of-care testing. Innovations and product launches in the Lateral Flow Assay space are expected to further drive market growth, making it a promising area for investment. (Sentiment: positive)
2025-08-08T23:07:57.704810+0800 INFO --------------------------------------------------
2025-08-08T23:07:57.704831+0800 INFO ENV-momentum: {'JNJ': 1}
2025-08-08T23:07:57.704851+0800 INFO ENV-symbol: ['JNJ']
2025-08-08T23:07:57.704871+0800 INFO ==================================================
2025-08-08T23:07:57.704905+0800 INFO AGENT-Step, date: 2020-03-19, run mode: RunMode.WARMUP, task type: TaskType.SingleAsset
2025-08-08T23:07:57.704927+0800 INFO AGENT-Handling new information
2025-08-08T23:07:57.988349+0800 INFO AGENT-Querying memories
2025-08-08T23:07:58.758383+0800 INFO ##################################################
2025-08-08T23:07:58.758761+0800 INFO AGENT-Queried memories for symbol: JNJ
2025-08-08T23:07:58.758860+0800 INFO AGENT-Short Memory: 19, ChroniSense Medical has appointed Bridget Ross as CEO, effective February 10, 2020. Ross brings over three decades of leadership experience, including roles at Henry Schein and Johnson & Johnson (J&J), where she led significant growth and operational efficiencies. Her appointment is expected to drive ChroniSense to a leading position in the disease management space with its Polso wearable device. This move highlights Ross's successful track record at J&J, particularly in commercial operations and product development. Investors in J&J might view this as a positive reflection of the company's ability to cultivate high-caliber leaders who are sought after by other innovative firms. (Sentiment: positive)
2025-08-08T23:07:58.758943+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759010+0800 INFO AGENT-Short Memory: 20, The global Lateral Flow Assay market is projected to grow by $3.8 billion, driven by a compounded annual growth rate (CAGR) of 7.4%, with the Kits & Reagents segment expected to grow at over 7.7% and reach $5.7 billion by 2025. The United States will maintain a 6.2% growth momentum, while China is expected to grow at 11%, adding approximately $1 billion in market opportunity. Key players in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMerieux SA, and Johnson & Johnson (JNJ). The market growth is driven by factors such as the expanding aging population, increase in chronic diseases, and rising popularity of point-of-care testing. Innovations and product launches in the Lateral Flow Assay space are expected to further drive market growth, making it a promising area for investment. (Sentiment: positive)
2025-08-08T23:07:58.759081+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759145+0800 INFO AGENT-Short Memory: 17, Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a New Drug Application (NDA) to the U.S. FDA for ponesimod, an investigational treatment for adults with relapsing multiple sclerosis (MS). The NDA is supported by the Phase 3 OPTIMUM study, which demonstrated ponesimod's superior efficacy in reducing annualized relapse rate (ARR) and fatigue symptoms compared to Aubagio. The study also showed a significant reduction in combined unique active lesions (CUALs) in the brain. The safety profile of ponesimod was consistent with previous studies and other S1P receptor modulators. Investors should note the potential market impact given the high prevalence of MS and the unmet needs in its treatment. (Sentiment: positive)
2025-08-08T23:07:58.759220+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759289+0800 INFO AGENT-Short Memory: 15, The Visiongain report projects the global Rheumatoid Arthritis (RA) drugs market to grow at a CAGR of 0.6% in the latter half of the forecast period, reaching $58 billion in 2018. The biologics submarket, which held 85% of the RA market in 2018, is a significant driver of this growth. Key players in the market include Johnson & Johnson (JNJ), which is well-positioned given its strong portfolio of RA drugs like Remicade and Simponi. The report provides detailed revenue forecasts by drug class, individual drugs, and regions, highlighting North America and Europe as leading markets. Investors should note the market's modest growth rate and the dominance of biologics, which could influence JNJ's strategic focus and investment in this sector. (Sentiment: neutral)
2025-08-08T23:07:58.759352+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759415+0800 INFO AGENT-Short Memory: 16, The global oral care market is projected to grow from USD 34,670 million in 2019 to USD 41,010 million by 2026, at a CAGR of 2.4%, driven by increasing dental health awareness and expenditure, and the rising prevalence of dental diseases. Key market segments include toothbrushes, toothpaste, mouthwash/rinse, denture products, and dental accessories, with toothpaste holding the largest market share. The Asia-Pacific region leads the market due to its large population, followed by Europe and North America. Major players in the market include Johnson & Johnson (JNJ), Procter & Gamble, Colgate-Palmolive, and GlaxoSmithKline. JNJ's involvement in the oral care market, particularly in high-demand regions and innovative product segments, positions it well for potential growth. (Sentiment: positive)
2025-08-08T23:07:58.759480+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759540+0800 INFO AGENT-Reflection Memory: 18, The positive price fluctuation of 0.0586 is likely influenced by the positive sentiment from short-term news (IDs 17, 16, 12) highlighting JNJ's advancements in pharmaceuticals (e.g., ponesimod NDA submission, RA drug portfolio strength, and surgical robotics growth). These developments may have boosted investor confidence in JNJ's innovation and market positioning, despite the reflection-term information (IDs 6, 14, 11, 1) noting that broader market factors or unmentioned events could also play a role.
2025-08-08T23:07:58.759602+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759661+0800 INFO AGENT-Reflection Memory: 11, The price fluctuation of -0.0744 for JNJ is not directly explained by the provided information, which includes neutral clinical trial data (ID 4) and positive news about partnerships (ID 7) and safety initiatives (ID 8). The absence of specific financial sentiment indicators or competitor-related news (IDs 6 and 1) suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:07:58.759723+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759780+0800 INFO AGENT-Reflection Memory: 6, The observed price fluctuation of -0.0708 for JNJ is not directly explained by the provided information, which includes neutral clinical trial reports and positive news about JNJ's COVID-19 vaccine collaboration. The lack of specific financial sentiment indicators or competitor-related news suggests the decline may be influenced by broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events. The reflection-term information (ID 1) explicitly states this absence of actionable data.
2025-08-08T23:07:58.759840+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.759900+0800 INFO AGENT-Reflection Memory: 14, The price fluctuation of 0.011933 for JNJ is not directly explained by the provided information. The available data includes neutral clinical trial details, positive news about partnerships and safety initiatives (IDs 7, 8), and a future investor call (ID 13). However, none of these factors are explicitly tied to the immediate price movement. The reflection-term information (IDs 1, 6, 11) indicates that such fluctuations may stem from broader market factors, sector-wide risks (e.g., pharmaceutical industry volatility), or unmentioned external events.
2025-08-08T23:07:58.759959+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.760010+0800 INFO AGENT-Reflection Memory: 1, The provided data lacks specific financial sentiment indicators or competitor-related news to explain the price fluctuation. Without short-term, mid-term, long-term, or reflection-term information, the observed decrease of -0.0708 for JNJ may be attributed to broader market factors, sector-wide risks, or unmentioned external events.
2025-08-08T23:07:58.760073+0800 INFO @@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@
2025-08-08T23:07:58.760134+0800 INFO AGENT-Single asset task
2025-08-08T23:08:25.389873+0800 INFO ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2025-08-08T23:08:25.778660+0800 INFO AGENT-action: TradeAction.BUY
2025-08-08T23:08:25.778770+0800 INFO AGENT-summary reason: The positive price fluctuation (0.0563557191517564) is likely driven by short-term positive sentiment (IDs 16, 17, 18) highlighting JNJ's pharmaceutical advancements, such as the ponesimod NDA submission (ID 17), strong RA drug portfolio (ID 15), and leadership appointments (ID 16). These developments reinforce investor confidence in JNJ's innovation and market positioning, particularly in disease management and healthcare technologies. The reflection-term information (ID 18) explicitly attributes this upward movement to such positive news, suggesting optimism about the company's future prospects despite broader market uncertainties mentioned in other IDs.
2025-08-08T23:08:25.779055+0800 INFO AGENT-feedback: {'access_counter_records': [{'id': 14, 'feedback': -1}]}
2025-08-08T23:08:25.899465+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:08:25.899768+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_checkpoint/env
2025-08-08T23:08:25.899839+0800 INFO **************************************************
2025-08-08T23:08:25.899893+0800 ERROR ENV-Date series exhausted
2025-08-08T23:08:25.899951+0800 INFO SYS-Environment exhausted.
2025-08-08T23:08:25.901703+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output/agent/memory_db/brain
2025-08-08T23:08:25.933442+0800 INFO ENV-Saving environment to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output/env
2025-08-08T23:08:25.933626+0800 INFO Path created: results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output/env
2025-08-08T23:08:25.933782+0800 INFO ENV-Environment saved to results/250808_230347_Qwen_Qwen3-8B_JNJ/warmup_output/env
2025-08-08T23:08:25.934449+0800 INFO  Warmup phase completed
2025-08-08T23:08:25.934504+0800 INFO  Step 2/3: Starting test phase
2025-08-08T23:08:25.935144+0800 INFO warmup: results/250808_230347_Qwen_Qwen3-8B_JNJ
